Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 31, Issue 6, Pages 632-635Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e31824acc33
Keywords
invasive aspergillosis; pediatric; voriconazole; pharmacokinetic; therapeutic drug monitoring
Categories
Funding
- H.A. and Edna Benning Foundation
- NIH/NIAID [1K23AI079401, 1U01AI082184-01]
- CDC [1U18IP000303-01, 1U181P000303]
- NCRR [3UL1RR025764-02S3]
- NICHD [HD060559-01, 5 R01 HD060559-02, 1K23HD064814-01]
- NIAID [1R01AI089489-01, U01-AI74419]
- nonprofit organization Thrasher Research Foundation
- Pfizer
- NIH CTSA [1UL 1RR024128-01]
- United States government [1R01HD057956-02, 1R01FD003519-01, 1U10-HD45962-06, 1K24HD058735-01, HHSN267200700051C]
Ask authors/readers for more resources
Voriconazole is the treatment of choice for invasive aspergillosis and its use is increasing in pediatrics. Minimal pharmacokinetic data exist in young children. We report voriconazole concentrations for 10 children <3 years of age and pharmacokinetic parameters for 1 infant who had therapeutic drug monitoring performed. Trough concentrations were unpredictable based on dose, highlighting the need to follow values during therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
